SCHOLAR ROCK HOLDING CORPORATION Revenue from Contract with Customer, Including Assessed Tax
SCHOLAR ROCK HOLDING CORPORATION (SRRK) reported Revenue from Contract with Customer, Including Assessed Tax of $3.11 million for the 3-month period ending 2019-03-31, per its 10-Q filed 2019-05-15.
Discontinued › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax · last filed 2019-05-15
- SCHOLAR ROCK HOLDING CORPORATION revenue from contract with customer, including assessed tax for the quarter ending 2019-03-31 was $3.11M.
| Period end | Revenue from Contract with Customer, Including Assessed Tax 3 month |
|---|---|
| 2019-03-31 | $3.11M 10-Q · filed 2019-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |